NASDAQ$COO

The Cooper Companies Inc · Q3 2022 earnings

Q3 2022 earnings · · Investor relations

Briefing

Reported record revenues with CooperVision and CooperSurgical's fertility business showing strong organic revenue growth.

CooperCompanies announced its fiscal third quarter results with revenue increasing by 10% year-over-year to $843.4 million. CooperVision's revenue increased by 2% to $566.3 million, while CooperSurgical's revenue increased by 35% to $277.1 million. GAAP diluted earnings per share were $1.98, and non-GAAP diluted earnings per share were $3.19.

  • Revenue increased 10% year-over-year to $843.4 million.
  • CooperVision (CVI) revenue up 2% to $566.3 million.
  • CooperSurgical (CSI) revenue up 35% to $277.1 million.
  • Non-GAAP diluted earnings per share $3.19, down 6% from last year's third quarter.

Headline financials

Total Revenue

$843M

Previous: $763M+10.5%
EPS (adj)

$0.80

Previous: $0.85-5.9%
GAAP Gross Margin

65.0%

Previous: 68.0%-4.4%
GAAP Operating Margin

17.0%

Previous: 13.0%+30.8%
Capital Expenditures

-$147M

Previous: -$149M+1.5%
Free Cash Flow

$415M

Previous: $415M-0.0%
Net Income

$98.4M

Previous: $616M-84.0%
Operating Income

$141M

Previous: $101M+39.8%
Gross Profit

$552M

Previous: $516M+7.0%
Cash & Equivalents

$246M

Previous: $112M+119.5%
Total Assets

$11.6B

Previous: $9.61B+20.2%

Revenue & EPS history

Cooper · Revenue · Quarterly

$843M

Q3 2022+10.5%vs Q3 2021
Beat estimate in 8 of 14 quarters(57%)
ActualEstimate

Revenue by segment

Cooper · $277M total across 2 segments · Q3 2022

  • Office and Surgical
    $165M+35.0%
  • Fertility
    $112M+33.9%

Forward guidance

The Company updated its fiscal year 2022 financial guidance.

Tailwinds

  • Fiscal 2022 total revenue $3,290 - $3,310 million (organic growth of 10% to 11%)
  • CVI revenue $2,236 - $2,247 million (organic growth of 11% to 12%)
  • CSI revenue $1,055 - $1,064 million (organic growth of 7% to 8%)
  • Fiscal 2022 non-GAAP diluted EPS $12.72 - $12.87
  • Fiscal fourth quarter 2022 total revenue $830 - $850 million (organic growth of 9% to 11%)

Headwinds

  • CVI revenue $554 - $565 million (organic growth of 8% to 10%)
  • CSI revenue $276 - $285 million (organic growth of 10% to 15%)
  • Fiscal fourth quarter 2022 non-GAAP diluted EPS $3.05 - $3.20
  • Fiscal year 2022 financial guidance does not include the Cook Medical Reproductive Health acquisition announced on February 7, 2022, as the transaction is pending regulatory approval.
  • Non-GAAP diluted earnings per share guidance excludes amortization and impairment of intangible assets, and other exceptional or unusual income or gains and charges or expenses including acquisition, integration and manufacturing related costs which we may incur as part of our continuing operations.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2022

Historical avgQ3 2022

+0.5%

Avg return

Earnings day

-0.5%

Avg return

5 days after

-0.1%

Avg return

30 days after

51%

35 / 68 earnings

Positive

+12.1%

Q3 2024

Best reaction

-12.8%

Q3 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-4.6%-8.0%-12.5%
Q4 2025-4.3%+4.8%+5.3%
Q3 2025-12.8%-11.8%-8.9%
Q2 2025+0.0%-0.3%+3.6%
Q1 2025-6.6%-13.1%-18.9%
Q4 2024-6.0%-5.6%-12.6%
Q3 2024+12.1%+12.1%+16.4%
Q2 2024+3.5%+3.8%-4.2%
Q1 2024+8.1%+7.3%+7.4%
Q4 2023-2.2%-0.7%+6.8%
Q3 2023-2.1%-3.5%-15.9%
Q2 2023-4.0%-5.1%+3.2%
Q1 2023+8.7%+3.9%+15.4%
Q4 2022-1.6%+4.8%+9.7%
Q3 2022+4.1%+2.5%-8.5%
Q2 2022-0.3%+1.3%-7.2%
Q1 2022+2.1%-8.5%+3.1%
Q4 2021+4.8%+8.7%+12.2%
Q3 2021+1.1%-0.7%-7.6%
Q2 2021-0.7%-3.2%+6.0%
Q1 2021+1.8%+0.3%+1.1%
Q4 2020+3.3%+3.3%+8.6%
Q3 2020+2.0%+0.3%+5.7%
Q2 2020-0.2%-5.0%-9.1%
Q1 2020-1.3%-0.9%-17.3%
Q4 2019-1.6%-2.4%+3.3%
Q3 2019-3.5%-6.7%-8.3%
Q2 2019+4.5%+9.0%+18.2%
Q1 2019-1.8%+0.1%+1.0%
Q4 2018-11.6%-7.3%-10.4%
Q3 2018-3.7%-3.4%+4.3%
Q2 2018+1.4%-0.4%+6.0%
Q1 2018+2.1%-3.8%-11.5%
Q4 2017-3.2%-1.9%-1.5%
Q3 2017-4.0%-2.5%-3.7%
Q2 2017+8.9%+10.5%+9.4%
Q1 2017-3.1%-3.6%-0.4%
Q4 2016+1.3%+4.1%+5.2%
Q3 2016+0.0%+1.3%-3.6%
Q2 2016-0.1%-0.4%+7.1%
Q1 2016+6.4%
Q4 2015-12.8%
Q3 2015-7.1%
Q2 2015-5.1%
Q1 2015+9.7%
Q4 2014-4.4%
Q3 2014+0.7%
Q2 2014+1.7%
Q1 2014+4.3%
Q4 2013-4.6%
Q3 2013-1.8%
Q2 2013+8.1%
Q1 2013+2.5%
Q4 2012+1.0%
Q3 2012+10.3%
Q2 2012-4.1%
Q1 2012+2.8%
Q4 2008+2.8%
Q4 2011+2.8%
Q3 2011-1.8%
Q2 2011+1.4%
Q2 2010+1.4%
Q1 2010+8.9%
Q1 2011+1.0%
Q4 2010-1.5%
Q3 2010+5.8%
Q3 2009+5.8%
Q4 2009+5.8%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro